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Aim To determine whether initiation of antibiotic therapy (ABX) by procalcitonin (PCT) within 8 h of admission in
patients presenting to the emergency department with symptoms and signs of acute heart failure (AHF) and elevated
natriuretic peptides would improve clinical outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
The study was a randomized multicentre clinical trial conducted at 16 sites in Europe. Patients were randomized
to either a PCT-guided strategy or standard care. Patients with PCT-guided strategy (n = 370) had ABX initiated
if PCT was > 0.2 μg/L. Patients with standard care (n = 372) had AHF care in accordance with published guidelines
without PCT. The primary endpoint was 90-day all-cause mortality. Pre-specified secondary endpoints included 30-day
all-cause mortality and readmission and rate of pneumonia. The Data Safety and Review Committee recommended
stopping the study for futility when 762 of the planned 792 patients had been enrolled. A total of 742 patients could
be analysed. Patients were elderly (median age: 77 years), 38% were women, and had typical signs and symptoms
of AHF. All-cause mortality at 90 days was 10.3% in the PCT-guided group vs. 8.2% in standard care (P = 0.316).
Thirty-day readmission was significantly higher in the PCT-guided group vs. standard care but the difference vanished
until day 90. The rate of pneumonia was overall low (7.5%) and not different between groups.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions In patients with AHF, a strategy of PCT-guided initiation of ABX was not more effective than a standard care strategy
in improving clinical outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Acute heart failure (AHF) is a serious condition with high short
and long-term mortality.1
A specific challenge is to identify infection as a trigger of AHF
or as the main reason for presentation, as infections have been
reported to accompany AHF events in 6.6–14%2,3 of all cases. Early
and correct detection of infections in the setting of AHF is difficult,
as typical symptoms of dyspnoea, fatigue, cough and dysuria may
be explained by infections and AHF, making a correct diagnosis
challenging. Chest X-ray and C-reactive protein also suffer from
low sensitivity in the setting of AHF.
The biomarker procalcitonin (PCT) has emerged as an alterna-
tive for C-reactive protein in diagnosing bacterial infection.4,5 PCT
is elevated in common bacterial infections such as pneumonia and
urogenital infections, which are very typical infections in AHF. Ret-
rospective analyses from heart failure patient subgroups in studies
using PCT for the guidance of antibiotic therapy (ABX),6 as well
as from diagnostic biomarker studies,7 suggested that PCT may
be useful for the decision to initiate or withhold ABX in patients
with suspicion of AHF presenting with dyspnoea to the emergency
department (ED). In a secondary analysis of the international multi-
centre Biomarkers in Acute Heart Failure (BACH) study,8 including
560 patients with the gold standard diagnosis of AHF, patients with
negative PCT had worse outcome if treated with antibiotics.7 The
prognostic value of PCT in AHF has been confirmed in several
other secondary analyses and observational studies as summarized
recently.9
In this randomized, international, multicentre, open study10 we
investigated whether initiation of ABX by PCT guidance in patients




The rationale and study design have been published previously.10 The
study protocol and the statistical analysis plan are provided as sup-
plemental material. The study was approved by the ethics commit-
tee of the leading institution (Charité – Universitätsmedizin Berlin;
EA4/025/16) and all local institutional review boards. All partici-
pants gave written informed consent. An independent Data Safety
and Review Committee (DSRC) was appointed by the study spon-
sor (Thermo Fisher BRAHMS GmbH) and monitored the study by
analysing outcome data after each quarter of enrolment. Audits to the
study site visits with in depth chart reviews of consented patients were
carried out by the principal investigator to ensure protocol adherence.
All patients underwent complete independent monitoring (source data
verification). The study was registered before enrolment of the first
patient (ClinicalTrials.gov, NCT02392689).
Study participants
Adult patients were eligible for enrolment if they presented to the
ED with the leading symptom of dyspnoea, suspected or known



















































































.. heart disease and/or functional cardiac dysfunction, accompanied by
an elevated level of a natriuretic peptide [N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) >1800 ng/L or B-type natriuretic peptide
> 350 ng/L or mid-regional pro-atrial natriuretic peptide (MR-proANP)
> 300 pmol/L].
Patients had to give written informed consent within study timelines
to allow ABX within 8 h after arrival in the ED, and hospitalization for at
least one planned overnight stay in the respective hospital was required.
Key exclusion criteria were trauma-related dyspnoea, diagnosis of
severe lung or thyroid cancer, a known terminal disease with life
expectancy of < 6 months, e.g. advanced metastatic cancer, end-stage
or severely advanced chronic heart failure defined by heart trans-
plantation listing or cardiogenic shock, current use of antibiotics or
requirement of immediate ABX before randomization and end-stage
renal failure requiring dialysis. The full list of exclusion criteria has been
published previosuly.10
Randomization and group assignment
Patients were randomized by concealed envelopes 1:1 via a
centre-stratified, balanced and blocked randomization procedure
to either a standard care group or a PCT-guided group with respect
to the initiation of an ABX. Given the nature of the study intervention,
the group assignment was not blinded.
For patients randomized to the PCT-guided strategy, the attending
emergency physicians were instructed to initiate ABX only if the PCT
value was > 0.2 μg/L at admission as outlined in detail elsewhere.10
A second PCT measurement at least 12 h after admission was per-
formed. Again, it was encouraged to start ABX if this second value
was > 0.2 μg/L, whereas ABX initiated based on an initial PCT value
> 0.2 μg/L should not be stopped if the second value was < 0.2 μg/L.
Further adjustments to the ABX for individual patients were at the
discretion of the treating physicians. Patients randomized to the
standard care group received ABX on the basis of regular clinical
decision making, following the respective local standards. Patients in
the standard care group had blood samples taken at the same time
intervals as the PCT-guided group. PCT levels were determined batch
wise for these patients and blinded to the investigators throughout
the whole study period.
Study outcomes
The primary endpoint was 90-day all-cause mortality. The 30-day
all-cause mortality rate, 30-day all-cause hospital readmission, and diag-
nosis of pneumonia during the index hospitalization were assessed
as pre-specified secondary endpoints.10 Additionally, a number of
exploratory endpoints were analysed, including 90 day all-cause hos-
pital readmission, which is also reported in this paper.
Additionally, the primary main diagnosis was adjudicated by two
independent blinded cardiologists. Adjudication was done separately
for each country of inclusion to avoid language-associated mistakes
regarding the chart reviews.
Procalcitonin measurement
Procalcitonin was measured from sample tubes as by standard practice
(serum or plasma), either with the B⋅R⋅A⋅H⋅M⋅S PCT sensitive KRYP-
TOR as described in the instruction manual or with the PCT assay
available for routine testing at the respective study sites. Other assays
than the B⋅R⋅A⋅H⋅M⋅S PCT sensitive KRYPTOR had to be approved by
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the steering committee to guarantee comparability of the PCT results.
The Elecsys B⋅R⋅A⋅H⋅M⋅S PCT (Roche) and the ADVIA Centaur®
B⋅R⋅A⋅H⋅M⋅S PCT (Siemens) were used in addition to the B⋅R⋅A⋅H⋅M⋅S
PCT sensitive KRYPTOR throughout the study.
Published analytical characteristics of the instruments were: overall
coefficients of variations ranged from 3.94% to 1.70% for B⋅R⋅A⋅H⋅M⋅S
PCT and from 6.57% to 1.90% for B⋅R⋅A⋅H⋅M⋅S PCT sensitive KRYP-
TOR. Limits of detection were 0.014 and 0.040 μg/L for B⋅R⋅A⋅H⋅M⋅S
PCT and B⋅R⋅A⋅H⋅M⋅S PCT sensitive KRYPTOR, respectively. The
functional assay sensitivity was 0.045 μg/L for B⋅R⋅A⋅H⋅M⋅S PCT and
<0.035 μg/L for B⋅R⋅A⋅H⋅M⋅S PCT sensitive KRYPTOR. B⋅R⋅A⋅H⋅M⋅S
PCT and B⋅R⋅A⋅H⋅M⋅S PCT sensitive KRYPTOR was linear up to
68.7 μg/L and up to 43 μg/L, respectively.11 Analytical characteristics
of the ADVIA Centaur® B⋅R⋅A⋅H⋅M⋅S PCT were similar.12
Gold standard diagnoses
Gold standard diagnoses were assigned country wise by two indepen-
dent cardiologists, specifically for the diagnoses ‘acute heart failure’ and
‘pneumonia’. Adjudicators were blinded to study arm but not blinded
to PCT levels. Agreement for primary diagnosis was 66%, for 34% adju-
dicators needed to review again and discuss to conclude finally on the
diagnosis. In the end, 100% agreement between adjudicators for pri-
mary diagnosis was achieved.
Statistical analysis
Based on a two-sided chi-square test for two independent proportions,
396 subjects per arm would have been sufficient to detect a 7%
difference in mortality (11% vs. 18%) at 5% significance level with a
power of 80% in a study design with fixed sample size. A two-stage
sample-size adaptive design according to Bauer and Kohne13 was used
in this study. The final sample size was planned to be calculated
based on the results of the interim analysis after the inclusion of
50% cases for primary analysis (log-rank test and Cox proportional
hazards regression for 90-day all-cause mortality). After finalization of
the interim analysis whose results were blinded to the investigators,
it was decided to maintain the originally planned sample size of 396
patients per study arm. No safety issues were detected.
The intention-to-treat (ITT) analysis as well as the safety population
included all randomized patients. For the per-protocol (PP) analysis, all
patients without major protocol deviations during study participation
were included, who were treated according to the PCT algorithm in
the PCT-guided group, and who did not have PCT measurement results
within 12 h of presentation to the ED in the standard care group. In
a sensitivity analysis, a second PP analysis was conducted expanding
the PCT-guided group of the PP population to all PCT-guided patients
without major protocol deviations and with PCT measured on day
0. The study sample was described with frequency counts for nom-
inal variables and means with standard deviations or medians with
interquartile ranges (IQR) for numerical variables as appropriate to
the distributional properties of variables. P-values were also computed
in order to facilitate a results overview (Wilcoxon rank sum test for
numerical variables, chi-square test for binary variables; no correction
of P-values for multiple testing). Standard uni- and bivariate statistics
were applied to check the success of randomization.
The primary study hypotheses were evaluated using log-rank test
and Cox proportional hazards regression of 90-day all-cause mortality
concerning standard care group and PCT-guided group. As sensitivity



















































































.. for Human Use (CHMP), 2013 guideline on adjustment for baseline
covariates (accessed 3 November 2015), study centres were also
included in Cox proportional hazards regression as additional cate-
gorical predictors. The significance of additional regression predictors
was assessed by likelihood ratio testing comparing the extended
model with additional predictor vs. the base model without. For
binary endpoints, percentage rates and counts were computed and
statistically evaluated by chi-square testing. Note that all reported
P-values are raw P-values, i.e. not corrected for multiple testing. 95%
confidence intervals (CIs) were computed according to Clopper and
Pearson. A significance level of 5% was used for all two-sided statistical
tests (2.5% for one-sided testing).
In order to evaluate the PCT cutoff of 0.2 μg/L pre-specified in the
study, we retrospectively varied the PCT cutoff along the range of
PCT concentrations observed in the study, defined PCT-negative and
PCT-positive patient strata accordingly (‘negative’ if PCT ≤ cutoff, else
‘positive’) and computed log-rank tests to compare patient survival
within 90-day follow-up time between patient strata. Significant sep-
aration between patient strata was expected for adequately chosen
PCT cutoffs. The strength of group separation was visualized by plots
of selected PCT-cutoff vs. resulting log-rank test P-value.
Safety analyses
A DSRC was responsible for ongoing, independent review of patient’s
safety and correct and timely execution of the processes described in
the protocol. Furthermore, deviations from the PCT-guided treatment
recommendations were monitored by the DSRC, to detect issues
related to the proposed treatment schedule. The DSRC conducted
their first study safety assessment after 198 patients (25% of the
originally planned sample size) had completed the 90-day follow-up.
The second meeting of the DSRC was held after 396 patients (50%
of the planned sample size) had completed the 90-day follow-up and
coincided with the efficacy interim analysis (see above and methods
paper10). The DSRC decided to have one further meeting after 75%
of the patients had completed their 3-month follow-up. After this
meeting, the DSRC recommended to stop the study prematurely due
to futility. The steering committee convened and discussed the detailed
recommendations. The study was stopped on 20 December 2017 after
the randomization of 762 patients. This number of patients was only 30
patients short of the planned sample size. The online supplementary
Figure S1 shows the recruitment chart of the study.
Results
Study patients
A total of 762 patients were enrolled at 16 sites in Germany,
Denmark, The Netherlands, and Spain between April 2015 and
December 2017 (Figure 1). Patient groups were generally well
balanced with respect to baseline characteristics (Table 1).14 The
study enrolled patients with high-risk AHF, as characterized by
high natriuretic peptides levels [median NT-proBNP concentration
5350 ng/L (IQR 3200–10 418) or median MR-proANP 504 pmol/L
(IQR 397–667). The selection of patients was sufficient as 80% of
patients had the gold standard main diagnosis of AHF.
The study was terminated prematurely as detailed above in
the Methods section (see also Figure 1 and online supplementary
Figure S1).
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Consort flow diagram of patient flow of the randomized study. ABX, antibiotic therapy; DSRC, Data Safety and Review Committee;
FU-follow-up; ITT, intention-to-treat; PCT, procalcitonin.
Table 1 Baseline characteristics of study patients
All patients (n = 742) PCT-guided (n = 370) Standard care (n = 372) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 77 (70–83) 77 (70–83) 77 (70–83) 0.812
Female sex 280 (38%) 132 (36%) 148 (40%) 0.281
BMI (kg/m2) 27.2 (24.6–31.1) 26.6 (23.7–30.8) 27.7 (25–31.6) 0.006
NT-proBNP (ng/L)a 5350 (3200–10 418) 5523 (3252–10 438) 5268 (3145–10 374) 0.498
MR-proANP (pmol/L)a 504 (397–667) 523 (439–733) 459 (378–624) 0.133
PCT (μg/L) 0.07 (0.05–0.13) 0.08 (0.05–0.13) 0.07 (0.05–0.13) 0.136
eGFR (mL/min) 63.5 (44.7–78.2) 64 (47.7–78) 62.9 (43.2–78.8) 0.420
eGFR <30 mL/min 80 (11%) 33 (9%) 47 (13%) 0.130
Hypertension 565 (76%) 280 (76%) 285 (77%) 0.831
CAD 347 (47%) 174 (47%) 173 (47%) 0.945
Known CHF 406 (55%) 208 (56%) 198 (53%) 0.457
Diabetes 267 (36%) 128 (35%) 139 (37%) 0.478
CKD 261 (35%) 123 (33%) 138 (37%) 0.307
BMI, body mass index; CAD, coronary artery disease; CHF, chronic heart failure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate (by Chronic
Kidney Diseaase Epidemiology Collaboration formula14); MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide;
PCT, procalcitonin.
aNT-proBNP was measured in 639 patients, MR-proANP was measured in 103 patients, B-type natriuretic peptide was measured in one patient. Concentrations of two
different natriuretic peptides were only available for 12 patients (NT-proBNP and MR-proANP).
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Primary (A) and secondary outcomes (B) in the Kaplan–Meier analysis. ITT, intention-to-treat; PCT, procalcitonin.
Primary outcome
Ninety-day all-cause mortality was considerably lower than
expected (8.2% observed vs. 18% expected for standard care,
ITT) and there was no significant difference in 90-day all-cause mor-
tality between the randomized groups (PCT-guided: 10.3%, 95%
CI 7.4–13.9%; standard care: 8.2%, 95% CI 5.6–11.5%; P = 0.316,
log-rank test; ITT) (Figures 2A and 3). Similar results were obtained
for 30-day all-cause mortality (PCT-guided: 6.8%, 95% CI 4.4–9.8%;
standard care: 4.3%, 95% CI 2.5–6.9%; P = 0.152, log-rank test;
ITT). The 30-day all-cause hospital readmission rate was signif-
icantly lower in the standard care group (PCT-guided: 17.3%,
standard care: 9.7%, P = 0.002, log-rank test), but this difference
was not sustained at 90 days (P = 0.913, log-rank test) (Figure 2B).
Also no difference between study arms was observed at 90 days
when multiple hospitalizations per patient were considered.
Treatment details and procalcitonin
levels
There were no significant differences in proportions of ABX
initiation between groups. The frequency of pneumonia was low
(7.5%; PCT-guided: 8.1%, standard care: 7.0%; P = 0.661) and the
duration of ABX was not different between randomized groups.
Also, intensive care unit and total length of stay were not different
(Table 2). The most frequent ABX were penicillin (23.2%, n =172),
cephalosporins (12.1%; n = 90), fluoroquinolones (5.1%; n = 38)
and macrolides (2.2%; n =16). The choice of antibiotics was
not reported in 52.4% (n = 389). In the PCT-guided group, the
median turnaround time for day 0 PCT measurements (time of
day 0 PCT measurement–time of patient presentation) was 4.1 h
(IQR 2.7–5.4 h). For those patients of the PCT-guided group that















































.. admission and first-dose therapy was 5.9 h (IQR 4.9–7.5 h). This
was not significantly different from the control group (median time
between admission and first-dose therapy: 5.5 h, IQR 3.9–7.9 h).
All results refer to the ITT patient population. When all within
study antibiotic treatments are considered, then time to first
antibiotic treatment seems shorter in the PCT-guided group than
in the standard care group (median in PCT-guided group: 118 h
vs. median in standard care: 180 h, difference almost significant
according to Wilcoxon rank sum test: P = 0.057).
Nine of 372 patients of the ITT standard care population had
PCT determined on day 0 within 12 h of presentation. For three of
these nine patients, day 0 PCT was above the cutoff 0.2 ng/mL. Two
of these three patients with above cutoff PCT received antibiotics
on day 0.
Secondary outcomes
Two pre-specified PP analyses were done: PP1 (n = 667) defined
the PCT-guided group as adherent with the PCT algorithm and the
standard care group having no (early) PCT on day 0. PP2 (n = 711)
defined the PCT-guided group as PCT measured on day 0 and
the standard care group having no (early) PCT on day 0. Figure 3
shows that the PP analyses revealed similar results compared to
the ITT analyses with no difference in 90-day mortality between
the randomized groups. Figure 3 also highlights the generally low
mortality in the study population, which was as low as the assumed
mortality of the PCT group.
Online supplementary Figure S2 shows the proportion of surviv-
ing patients for the entire study population splitted by day 0 PCT
levels at the decision cutoff 0.2 μg/L of the study. Patients with
higher PCT levels had a significantly higher mortality (P < 0.001,
log-rank test). Similar statistical significances were obtained for
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Binary endpoints of the intention-to-treat (ITT) and per-protocol (PP) populations. PP1 (n = 667) is defined as follows: procalcitonin
(PCT)-guided: adherent with PCT algorithm, standard care: no PCT on day 0. PP2 (n = 711) is defined as follows: PCT-guided: PCT measured
on day 0, standard care: no PCT on day 0. pct, PCT-guided group; std, standard care group.
Table 2 Antibiotic therapy initiation
All patients (n = 742) PCT-guided (n = 370) Standard care (n = 372) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ABX initiated 117 (16%) 66 (18%) 51 (14%) 0.145
GSD AHF 594 (80%) 300 (81%) 294 (79%) 0.544
a
PCT > 0.2 μg/L
122 (16.4%) 61 (16.5%) 61 (16.4%) 0.921
EP 2.1: 30-day all-cause mortality 41 (5.5%) 25 (6.8%) 16 (4.3%) 0.196
EP 2.2: All-cause hospital readmission within 30 days 100 (13.5%) 64 (17.3%) 36 (9.7%) 0.004
EP 2.3: Pneumonia diagnosis during index
hospitalization
56 (7.5%) 30 (8.1%) 26 (7%) 0.661
EP 3.1: Number of patients on ABX 117 (15.8%) 66 (17.8%) 51 (13.7%) 0.145
EP 3.2: Duration of initial ABX (days) 8 (6–11) 8 (6–11.5) 8 (7–11) 0.659
EP 3.3: Total hospital length of stay (days) 8 (4–14) 7 (4–14) 8 (4–13) 0.863
EP 3.4: ICU length of stay (days) 3 (1.5–8) 3 (2–8.3) 3 (1–6.5) 0.316
EP 3.5: Need for second-line or additional ABX 67 (9.0%) 36 (9.7%) 31 (8.3%) 0.592
EP 3.6: In-hospital pulmonary complications other
than pneumonia (i.e. lung abscess, empyema,
acute respiratory distress syndrome) and other
bacterial infections during index hospitalization
102 (13.7%) 48 (13.0%) 54 (14.5%) 0.614
EP numbers refer to the SAP in the supplemental materials.
ABX, antibiotic therapy; AHF, acute heart failure; EP, endpoint; GSD, gold standard diagnosis; ICU, intensive care unit; PCT, procalcitonin.
aAt day 0 and/or day 1 (see Methods).
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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cutoffs around the pre-specified study cutoff [P < 0.001 for all
cutoffs between 0.05–0.35 μg/L; online supplementary Figure S3).
The additional inclusion of the factor randomized groups in
Cox proportional hazards regression was not statistically justified
(P = 0.254; likelihood ratio test), neither was the additional inclu-
sion of the interaction between randomized groups and day 0 PCT
levels (P = 0.219; likelihood ratio test).
Treatment adherence
Treatment non-adherence was caused by either violation of the
PCT algorithm in the PCT-guided group or availability of PCT to
the physician in the standard care group. Accordingly, the number
of PCT-guided patients was reduced from 370 (ITT) to 308 patients
(PP1), which corresponded to 83% adherence in the PCT-guided
group. Analogously, the number of standard care patients was
reduced from 372 (ITT) to 359 patients (PP1), which corresponded
to 97% adherence in the standard care group.
The largest sources of violations were: (i) initiating antibiotics
on day 0 in spite of below-threshold day 0 PCT (n = 22); (ii) day 0
PCT not available within 8 h (n = 16); (iii) not initiating or not early
enough initiating antibiotics on day 0 in spite of above-threshold
day 0 PCT (n = 14); or (iv) not initiating antibiotics on day 1
after below-threshold day 0 PCT and above-threshold day 1 PCT
(n = 11).
Centre effect
Patients were enrolled at 16 clinical study centres with consider-
ably varying sample sizes from 169 to 1 ITT patient.
Centre-specific 90-day all-cause mortality estimates showed
widely overlapping 95% CIs (online supplementary Figure S4). The
inclusion of the covariate clinical study centre in a Cox pro-
portional hazards regression model for 90-day all-cause mortality
in addition to the main predictor study arm was not significant
according to likelihood ratio testing of hierarchical model compar-
ison (P = 0.065).
Discussion
The randomized IMPACT EU study evaluated if PCT-guided initi-
ation of ABX in patients presenting with AHF would be superior
over regular clinical decision making with regard to clinical out-
comes. The results show that PCT-guided initiation of ABX confers
no clear benefits, and neither the primary endpoint (90-day mor-
tality) nor any of the secondary endpoints hinted towards a benefit
of PCT-guided ABX.
The study was terminated due to futility by the DSRC on the
basis of the data of 75% of enrolment. As the analysis could only
be done after completion of the 3-month follow-up and a slightly
increased recruitment rate occurred in the final phase of study
recruitment, once terminated, the number of patients included was
only 30 patients short of the originally planned number (Figure 1
and online supplementary Figure S1).
In our study, patients were identified in the ED from presentation



















































































.. been shown recently in a post-hoc analysis of the diagnostic BACH
study8 that patients with other primary diagnoses than AHF may
have also high natriuretic peptide levels and very high mortality15
as a potential bias for interventions that target heart failure. In
our study, gold standard diagnosis of AHF was prevalent in 80% of
patients, which shows that patient selection was sufficiently done.
Nevertheless, the population studied is somewhat unique as many
other cohorts of AHF patients are included only after ED care and
have a higher prevalence of pre-existing heart failure.16 Patients
were not characterized with respect to their functional status
(New York Heart Association class) and vital signs (blood pressure,
respiratory rate, heart rate), which limits the comparability to
other dyspnoea studies.
Mortality was much lower than was estimated10 (Figure 3). In
general, contemporary heart failure studies without exemption
show lower mortality rates than a decade ago, which must be
taken into account in future trial design. The reasons for this
may be diverse, but inclusion bias is an obvious explanation. The
very ill patients generally are excluded from studies, including
IMPACT EU, but mortality is generally the highest in patients with
severe co-morbid conditions. Further, recent data have shown that
telemedicine in patients with heart failure can reduce mortality17
and that the mechanism of the effect is most probably the inten-
sified care by specialized nurses and doctors, which leads to the
improved outcome in a multi-modal way, e.g. better adherence to
treatment, earlier adjustment of medical drugs, and psycho-social
coaching.
Furthermore, the PCT cutoff used could have been suboptimal
for the intervention. We therefore performed a post-hoc analysis
of the PCT cutoffs with respect to the result of a log-rank test
for the prediction of mortality. In this analysis we found that PCT
cutoffs between 0.10 and 0.50 μg/L had similar performance with
the optimum between 0.20 and 0.25 μg/L, lending support for the
cutoff used in the study (online supplementary Figure S3).
The most challenging task for treating physicians is the diag-
nosis of AHF among patients at intermediate pre-test probability
because natriuretic peptides improve correct classification.18 In
analogy, PCT was reported to improve diagnosis of severe infection
among patients at a medium pre-test probability of pneumonia.7
The post-hoc analysis of the BACH trial8 suggested that a com-
bined testing of natriuretic peptides in combination with PCT
would avoid unnecessary antibiotic administration in heart fail-
ure patients, or conversely unnecessary heart failure treatment in
patients with pneumonia. Thus, ideally physicians should have been
blinded to both biomarker results in equivocal clinical presenta-
tions. Controversially, the IMPACT EU study restricted inclusion to
patients at high pre-test probabilities of AHF based on (very) high
natriuretic peptide levels exceeding the rule-in cutoff for patients
aged ≥75 years to prospectively find the AHF group, which has
been defined retrospectively in the BACH secondary analysis.7 This
pre-selection reduces the risk for inappropriate treatment of heart
failure and thus the potential benefits of a combined biomarker
strategy. Furthermore, patients with current ABX were excluded
from the IMPACT EU study. Thus, the prevalence of severe infec-
tion was low, which might also have impacted the low mortality by
systematic exclusion of more severe cases. In this cohort with a low
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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rate of severe infections also the benefits of PCT over other rou-
tinely available biomarker including C-reactive protein, leucocytes,
and fever might become less important.
Recently, the ProACT study19 on 1656 patients in 14 US hospi-
tals reported about the usefulness of PCT guidance in suspected
lower respiratory tract infection. There was no significant differ-
ence in days of ABX or adverse outcomes between the PCT-guided
arm and standard care. Among others, it has been hypothesized
that the PCT result was almost universally disregarded in patients
with pneumonia.20 This unexpected finding might be attributed
to lack of guideline adherence in both directions, i.e. overuse of
antibiotics in low PCT tiers and underuse of PCT in high PCT
tiers, presumably due to the absence of an antimicrobial steward-
ship programme.21 In addition, this trial mostly enrolled low-risk
patients with pneumonia with unexpectedly low event rates.19
The intervention done in IMPACT EU was the initiation of ABX
mainly based on a single PCT level within the first 8 h of admission
for AHF. A second measurement was done on the next day (at least
12 h from admission), mostly for safety reasons. The further course
of ABX was left to the discretion of the attending physician.10 The
rationale behind this concept was based on retrospective analyses
of observational studies.6,7,10 On the other hand, interventional
studies in lower respiratory tract infections with the use of PCT
mainly showed that mortality was stable if ABX was shortened
and usually daily PCT measurements were done. The latter was
also the case in the only study which shows improvement of
outcome in intensive care patients where ABX was guided by daily
PCT measurements.22 In a recent commentary, van Oers et al.23
pointed out that retrospectively assessed single PCT measurement
guidance maybe insufficient for prospective use because results are
flawed in the post-hoc analyses. PCT has a certain value as a marker
of risk stratification (online supplementary Figure S2), but our
intervention based on PCT was not effective to lower mortality,
calling into question if elevated PCT values are only a marker of
worse outcomes, or they directly reflect a disease (infection) that
would be easily amenable to treatment. In summary, we think that
besides the overall low mortality, the intervention was too weak
and further studies should use serial PCT measurements to guide
(stop or continue) ABX. Furthermore, it should be considered
whether more sick patients were systematically excluded due to
their inability to provide written informed consent and thus a
cohort with a lower mortality was selected. Future studies could
also consider to apply for an exception of informed consent or a
delayed patient consent to avoid selection bias.
Finally, 7.5% of patients suffered from pneumonia and ABX initi-
ation was not different between the randomized groups (Table 2).
We postulate that within this study in tertiary (expert) centres,
the participating clinicians have effectively avoided to randomize
patients in whom they suspected pneumonia, excluding them due
to the anticipated requirement of immediate ABX. In addition, they
might not have trusted the PCT signal and wanted to avoid a study
advice which was against their clinical judgement, although overrul-
ing was allowed within IMPACT EU. Moreover, also other infections
could have been present (urinary tract infections, soft tissue infec-
tions) that might have influenced ABX initiation and study enrol-



















































































.. infections was too low in the end for PCT-guided treatment to
show a meaningful difference. PCT-guided treatment did not work
in all-comers and future studies should evaluate PCT-guided treat-
ment in AHF patients where antibiotics are considered based on
initial clinical judgement.
Limitations
The study aimed to enrol 396 subjects per arm to detect a 7%
difference in mortality (11% vs. 18%). However, the actual event
rates were much lower reducing the ability to detect significant dif-
ferences between randomized groups. Reasons for enrolment of a
low-risk cohort are illusive but might involve the triage process,
patient mix, the hospital setting, or a more efficacious treatment
in experienced academic institutions. PCT was discouraged but per
se available in most centres also for control patients and therefore
could have influenced antibiotic use in some controls. In addition,
the lack of more specific inclusion criteria like jugular venous dis-
tention, criteria of congestion from chest X-ray or lung ultrasound
contribute to heterogeneity of the study population. Furthermore,
it should be considered whether more sick patients were system-
atically excluded due to their inability to provide written informed
consent and thus a cohort with a lower mortality was selected.
Finally, specific information on other types of bacterial infection
than pneumonia was not assessed in detail and information on the
type of antibiotics given is incomplete, which limits further explana-
tory sub-analyses for outcome. Future studies could also consider
to apply for an exception of informed consent or a delayed patient
consent to avoid selection bias.
Conclusions
In patients with a high likelihood of AHF, including those with
confirmed AHF, a strategy of PCT-guided initiation of ABX was
not more effective than a standard care strategy in improving
outcomes.
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Figure S1. Recruitment of patients over time compared to the
recruitment plan in the last quarter of the study.
Figure S2. Analysis of the prognostic impact of procalcitonin at
the study cutoff in a post-randomization cohort of all patients in
the study.
Figure S3. Dependence of log-rank test P-value comparing
90-day all-cause mortality of procalcitonin (PCT)-positive vs.
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